- Home
- VIGL vs ME Comparison
VIGL vs ME Comparison
Compare VIGL & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ME
- Stock Information
- Founded
- VIGL 2020
- ME 2006
- Country
- VIGL United States
- ME United States
- Employees
- VIGL N/A
- ME N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ME Precision Instruments
- Sector
- VIGL Health Care
- ME Health Care
- Exchange
- VIGL Nasdaq
- ME Nasdaq
- Market Cap
- VIGL 95.2M
- ME 98.7M
- IPO Year
- VIGL 2022
- ME N/A
- Fundamental
- Price
- VIGL $2.08
- ME $3.58
- Analyst Decision
- VIGL Strong Buy
- ME Hold
- Analyst Count
- VIGL 5
- ME 1
- Target Price
- VIGL $19.75
- ME $9.40
- AVG Volume (30 Days)
- VIGL 331.7K
- ME 226.1K
- Earning Date
- VIGL 11-07-2024
- ME 02-05-2025
- Dividend Yield
- VIGL N/A
- ME N/A
- EPS Growth
- VIGL N/A
- ME N/A
- EPS
- VIGL N/A
- ME N/A
- Revenue
- VIGL N/A
- ME $193,260,000.00
- Revenue This Year
- VIGL N/A
- ME $21.93
- Revenue Next Year
- VIGL N/A
- ME $17.31
- P/E Ratio
- VIGL N/A
- ME N/A
- Revenue Growth
- VIGL N/A
- ME N/A
- 52 Week Low
- VIGL $1.49
- ME $2.66
- 52 Week High
- VIGL $6.06
- ME $16.52
- Technical
- Relative Strength Index (RSI)
- VIGL 55.12
- ME 49.65
- Support Level
- VIGL $1.79
- ME $3.34
- Resistance Level
- VIGL $2.02
- ME $3.95
- Average True Range (ATR)
- VIGL 0.16
- ME 0.29
- MACD
- VIGL 0.08
- ME 0.02
- Stochastic Oscillator
- VIGL 96.72
- ME 41.75
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.